Antibiotic Therapy: The Cornerstone of Iatrogenic Resistance to Immune Checkpoint Inhibitors

Menée au Canada à partir de données portant sur 2 737 patients âgés atteints d'un cancer (âge : supérieur ou égal à 65 ans), cette étude analyse l'association entre une utilisation d'antibiotiques antérieure au traitement par inhibiteurs de points de contrôle immunitaire et la survie globale

Résumé en anglais

The past decade has been testament to the diffusion of immune checkpoint inhibitors (ICIs) as part of the therapeutic armamentarium of nearly every oncologic indication. The unquestionable advances in the management of solid and hematologic malignancies ushered by selective modulation of programmed cell-death 1, cytotoxic T-lymphocyte–associated protein 4, and a growing additional number of putative actionable drivers of anticancer immunity have been accompanied by the compelling need to identify tumor and host-intrinsic mechanisms that underscore the effectiveness of these therapies.